FDAnews
www.fdanews.com/articles/186629-edwards-gains-ce-mark-for-transcatheter-tricuspid-therapy

Edwards Gains CE Mark for Transcatheter Tricuspid Therapy

May 1, 2018

Edwards received a CE Mark for its Cardioband tricuspid valve reconstruction system, a transcatheter therapy used to treat tricuspid heart valve disease.

The therapy uses the same implant technique and design as the company’s Cardioband mitral system and is not yet approved for sale in the U.S.

The device can be positioned precisely to a patient’s anatomy and allows real-time adjustment with simultaneous result confirmation.

View today's stories